Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mesoblast Limited (MEOBF)
OTHER OTC:MEOBF
Holding MEOBF?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-$0.03Last Year’s EPS
-$0.02Same Quarter Last Year
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 20, 2024
|% Change Since: 111.54%
|Next Earnings Date:Feb 20, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials and regulatory designations, alongside effective cost reduction strategies. However, the financial results reveal ongoing challenges with limited revenue and significant losses. The company's future financial stability appears to hinge on strategic partnerships and regulatory approvals.Company Guidance
During the earnings call for Mesoblast, the company provided comprehensive guidance on its clinical and financial progress. The call highlighted the successful completion of a pivotal Phase III trial for Remestemcel in pediatric steroid-refractory acute graft versus host disease, showing a primary endpoint achievement and long-term survival benefit of over four years. Furthermore, a new potency assay for Remestemcel was submitted to the FDA, with a meeting planned for March. The potential market for adult indications, which is five times larger, is underlined by collaborations for a pivotal trial. Financially, Mesoblast reported cash reserves of USD 77.6 million, a 25% reduction in quarterly cash burn, and a 21% reduction in loss after tax, resulting in a loss of USD 32.5 million. The company's strategy includes maintaining reduced operating expenses and seeking strategic partnerships to extend cash runway beyond 12 months.Completion of Pivotal Phase III Trial for Pediatric GVHD
A pivotal Phase III trial for pediatric steroid-refractory acute graft versus host disease successfully met its primary endpoint, showing long-term survival benefits lasting over 4 years.
Regulatory Progress for Remestemcel
New data from a second potency assay has been provided to the FDA, and a meeting is scheduled in March to discuss potential approval pathways.
Successful Cost Containment Strategies
Cash burn for operating activities was reduced by 25% in the last quarter compared to the same period in FY 2023.
Rare Pediatric Disease Designation
Revascor received both rare pediatric disease designation and orphan drug status from the FDA for treating hypoplastic left heart syndrome based on promising trial results.
RMAT Designation for Chronic Low Back Pain
Rexlemestrocel received RMAT designation for chronic low back pain, with a pivotal Phase III trial underway to potentially support FDA approval.
---
MEOBF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MEOBF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 20, 2024 | $1.04 | $1.02 | -1.92% |
| Aug 28, 2024 | $0.66 | $0.66 | 0.00% |
| May 29, 2024 | $0.84 | $0.81 | -3.57% |
| Feb 28, 2024 | $0.20 | $0.19 | -5.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mesoblast Limited (MEOBF) report earnings?
Mesoblast Limited (MEOBF) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Mesoblast Limited (MEOBF) earnings time?
Mesoblast Limited (MEOBF) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MEOBF EPS forecast?
MEOBF EPS forecast for the fiscal quarter 2025 (Q2) is -$0.03.
---